cl 1

Genevant CL1 (lipid 10) is an ionisable lipid (pKa=6.3) suitable for preparing lipid nanoparticles (LNP) for delivering nucleic acid payloads and intramuscular vaccines.

Genevant CL1 monohydrochloride is an ionizable cationic lipid (lipid 10, pKa=6.3) used for the delivery of mRNA lipid nanoparticles (LNP) in vaccine applications.

SST0116CL1 is an HSP90 inhibitor (IC50: 0.21 μM) that targets the ATP-binding pocket of Hsp90, disrupting its chaperone function and leading to the degradation of client proteins (EGFR, CDK4, and AKT). It induces the degradation of Her2 in BT-474 cells (IC50: 0.2 μM) and exhibits antiproliferative activity, inhibiting tumor growth.

Azido-PEG1-CH2COO-Cl (compound 43a) is an alkyl/ether-based PROTAC linker commonly used in the synthesis of PROTAC BRD4 Degrader-1[1].

Dox-Ph-PEG1-Cl, also referred to as PROTAC Linker 34, is a PEG-based compound employed for the synthesis of PROTACs[1].

Boc-C1-PEG2-C4-Cl (PROTAC Linker 1) is a PEG-based compound used as a linker in the synthesis and development of PROTACs[1].

steroidal androgen receptor agonist

Cl-Necrostatin-1 is an inhibitor of receptor-interacting protein kinase. It inhibits RIPK1 activity.

[Cu2Cl2(4'-(4-Methoxy-1-naphthyl)-terpy)2](PF6)2 (Compound 3) is a copper complex known for suppressing cell viability in HCT116, HCT116DoxR, A2780, and fibroblasts, with IC50 values of 0.13, 0.15, 0.66, and 6.24 μM, respectively. It induces apoptosis and autophagy at the G0/G1 cell cycle phase and exhibits anti-metastatic properties.

Pharmatose DCL 14 (D-Lactose monohydrate) is the major sugar present in milk and the main source of energy supplied to the newborn mammalian in its mother's milk. Pharmatose DCL 14 is also an important osmotic regulator of lactation. It could regulate human's intestinal microflora.

apamin-sensitive Ca2+-activated K+ channel (KCa2.1) blocker

CL 118326 is a phospholipase A2 inhibitor.

Pharmatose DCL 14 (Standard) is the standard substance of Pharmatose DCL 14, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Pharmatose DCL 14 (D-Lactose monohydrate) is the major sugar present in milk and the main source of energy supplied to the newborn mammalian in its mother's milk. Pharmatose DCL 14 is also an important osmotic regulator of lactation. It could regulate human's intestinal microflora.

MIK665 (S-64315) (S-64315) has an inhibitory effect on myeloid leukemia.

ABT-737 is a BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w (EC50=30.3 nM/78.7 nM/197.8 nM). ABT-737 exhibits antitumor activity and anti-aging activity.

Puromycin dihydrochloride (CL13900 dihydrochloride) is a cinnamamide adenosine antibiotic and an inhibitor of protein synthesis. Puromycin dihydrochloride inhibits protein synthesis by binding to RNA and has antitumor and antitrypanosomal activity.

S63845 is a selective myeloid leukemia 1(MCL1) inhibitor that binds to human MCL1 with a Kd of 0.19 nM.

dMCL1-2 is a potent and selective myeloid leukemia 1 (MCL1) degrading agent based on PROTAC, binding to MCL1 with a KD of 30 nM and activating the apoptosis mechanism by degrading MCL1.

A09-003 is a novel cell cycle protein-dependent kinase-9 CDK-9 inhibitor.A09-003 inhibits the proliferation of a variety of leukemia cell lines and inhibits the increase of leukemia sequence-1 protein in myeloid cells.A09-003 also induces apoptosis, decreases RNA polymerase II activity, and decreases Mcl-1 expression.

Sulfamethoxypyridazine (CL 13494) is a sulfanilamide antibacterial agent.

Tannic acid (Gallotannic acid) is a novel hERG channel blocker.

BT2, a BCKDC kinase (BDK) inhibitor, exhibits an IC50 of 3.19 μM and functions as a potent, selective Mcl-1 inhibitor with a Ki value of 59 μM. Its interaction with BDK induces helix movements in the N-terminal domain, leading to BDK's dissociation from the branched-chain α-ketoacid dehydrogenase complex (BCKDC).

Methotrexate (WR19039) is a folate analog, an inhibitor of the dihydrofolate reductase DHFR. Methotrexate has antimetabolic, antitumor, and immunosuppressive activities, and is commonly used in rheumatoid arthritis and various tumors.

Plerixafor (AMD-3329), a chemokine receptor antagonist, blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4.